NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.

被引：0
|
作者：
Kim, G. P.
Oberg, A.
Kabat, B.
Sing, A.
Hedrick, E.
Campbell, D.
Alberts, S.
机构：
[1] N Cent Canc Treatment Grp, Rochester, MN USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] SanofiAventis, Bridgewater, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4113
引用
收藏
页码：206S / 206S
页数：1
相关论文
共 50 条
  • [1] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
    Kim, George P.
    Oberg, Ann L.
    Foster, Nathan R.
    Sargent, Daniel J.
    Jaslowski, Anthony
    Campbell, Deborah
    Hedrick, Eric
    Grothey, Axel F.
    Alberts, Steve R.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 310 - 310
  • [2] Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
    Kim, G. P.
    Oberg, A. L.
    Foster, N. R.
    Jaslowski, A.
    Flynn, P. J.
    Campbell, D.
    Hedrick, E.
    Gray, L.
    Grothey, A.
    Alberts, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Foster, N. R.
    Salim, M.
    Flynn, P. J.
    Moore, D. F.
    Zon, R.
    Mowat, R. B.
    Wiesenfeld, M.
    McCullough, A. E.
    Alberts, S. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase II trial of high-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, W
    Kornek, G
    Ulrich-Pur, H
    Raderer, M
    Fiebiger, W
    Zickero, G
    Pidlich, J
    Greul, R
    Schneeweiss, B
    Depisch, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S147 - S147
  • [5] A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma
    Ulrich-Pur, H
    Kornek, GV
    Raderer, M
    Haider, K
    Kwasny, W
    Depisch, D
    Greul, R
    Schneeweiss, B
    Krauss, G
    Funovics, J
    Scheithauer, W
    [J]. CANCER, 2000, 88 (11) : 2505 - 2511
  • [6] Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma - Results of a phase II trial
    Dragovich, Tomislav
    Burris, Howard, III
    Loehrer, Patrick
    Von Hoff, Daniel D.
    Chow, Sherry
    Stratton, Steven
    Green, Sylvan
    Obregon, Yrma
    Alvarez, Irene
    Gordon, Michael
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (02): : 157 - 162
  • [7] Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    Fogelman, David
    Jafari, Mehrdad
    Varadhachary, Gauri R.
    Xiong, Henry
    Bullock, Susie
    Ozer, Harold
    Lin, E.
    Morris, Jeffrey
    Cunningham, Patti
    Bennett, Bronwyn
    Abbruzzese, James L.
    Wolff, Robert A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1431 - 1438
  • [8] A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
    Ma, CX
    Steen, P
    Rowland, KM
    Niedringhaus, RD
    Fitch, TR
    Kugler, JW
    Hillman, DW
    Perez, EA
    Ingle, JN
    Adjei, AA
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (02) : 226 - 231
  • [9] Phase II trial of vatalinib in patients with advanced or metastatic pancreatic adenocarcinoma who failed gemcitabine therapy
    Dragovich, T.
    Laheru, D. A.
    Crowley, J. J.
    Smith, L. S.
    Seng, J.
    Burris, H. A., III
    Rosen, P. J.
    Von Hoff, D. D.
    Bolejack, V.
    Hidalgo, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
    A Demols
    M Peeters
    M Polus
    R Marechal
    F Gay
    E Monsaert
    A Hendlisz
    J L Van Laethem
    [J]. British Journal of Cancer, 2006, 94 : 481 - 485
12345